In this emergency episode, John Kitchens, MD, and Scott Krzywonos break down the newly announced SOL-1 study data evaluating Axpaxli (Ocular Therapeutix) for wet AMD — a superiority trial comparing a single Axpaxli injection to a single Eylea injection in patients who had received a pair of monthly Eylea doses.

Key findings include 74% of Axpaxli patients maintaining vision at 36 weeks versus 59% in the Eylea arm, with approximately 75% requiring no rescue treatment through 36 weeks and some patients achieving durable disease control out to 52 weeks.

John and Scott discuss what the FDA-aligned superiority endpoint means for the results, why the market reaction diverged from clinical enthusiasm, how to talk to patients who hear about the data, and what to expect from the SOL-R study and a potential FDA submission.

Why It Matters

For the first time in years, retina specialists may be looking at a new mechanism of action — a tyrosine kinase inhibitor — with the potential to significantly extend treatment intervals after a single injection. More detailed analysis and expert commentary coming soon on RetinUp.